Achillion Pharmaceuticals Inc. (ACHN) announced it has initiated an international Phase 2 clinical trial with sovaprevir and ACH-3102 for the treatment of genotype 1 chronic hepatitis C. The trial will evaluate an all-oral 12-week interferon-free regimen consisting of sovaprevir, ACH-3102, and ribavirin in patients with chronic HCV who have not received prior therapy.
Achillion expects reporting all-oral results from ongoing clinical trials including RVR results from the -007 sovaprevir and ACH-3102 study during the third quarter of current year, as well as providing the updated SVR results later this month from safety and tolerability study of ACH-3102 and ribavirin for the treatment of genotype 1b HCV.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.